Cameroon vs Cote d'Ivoire: Prevalence rate of hypertension in adults aged 30-79
Cameroon
36.8
in 2019
Cote d'Ivoire
37.3
in 2019
Cameroon rank
109th
Cote d'Ivoire rank
107th
Prevalence rate of hypertension in adults aged 30-79 over time
- Cameroon
- Cote d'Ivoire
How they compare
Cote d'Ivoire currently reports 37.3 against 36.8 in Cameroon, a difference of 0.5.
Across all 30 years both countries report, Cote d'Ivoire has been ahead every year.
Cameroon ranks 109th and Cote d'Ivoire ranks 107th of 194 countries.
Cote d'Ivoire has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Cameroon | Cote d'Ivoire | Difference | Ahead |
|---|---|---|---|---|
| 1990s | 33.46 | 37.09 | 3.63 | Cote d'Ivoire |
| 2000s | 34.91 | 38.61 | 3.7 | Cote d'Ivoire |
| 2010s | 36.49 | 38.11 | 1.62 | Cote d'Ivoire |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher prevalence rate of hypertension in adults aged 30-79, Cameroon or Cote d'Ivoire?
- Cote d'Ivoire, at 37.3 against 36.8 in Cameroon as of 2019.
- What is the difference in prevalence rate of hypertension in adults aged 30-79 between Cameroon and Cote d'Ivoire?
- 0.5, with Cote d'Ivoire ahead.
- How many years of comparable data are there for Cameroon and Cote d'Ivoire?
- 30 years are reported by both, from 1990 to 2019.
- How do Cameroon and Cote d'Ivoire rank globally for prevalence rate of hypertension in adults aged 30-79?
- Cameroon ranks 109th and Cote d'Ivoire ranks 107th of 194 countries.
- Where does this data come from?
- World Health Organization - Global Health Observatory (2026) – with minor processing by Our World in Data, published as Prevalence rate of hypertension in adults aged 30-79. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Estimated share of the population with hypertension, based on population representative surveys and statistical modeling. Hypertension is a risk factor for chronic complications, including cardiovascular disease, and premature death.